Pre-Made Dazodalibep Biosimilar, Fusion Protein targeting CD40LG fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-798

Pre-Made Dazodalibep Biosimilar, Fusion Protein targeting CD40LG fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dazodalibep is a novel, non-antibody fusion protein that blocks CD40 ligand (CD40L) activity that has been shown to reduce B cell activation and autoantibody production, potentially halting inflammation and autoimmunity.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-798-1mg 1mg 3090
GMP-Bios-INN-798-10mg 10mg Inquiry
GMP-Bios-INN-798-100mg 100mg Inquiry
GMP-Bios-INN-798-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Dazodalibep Biosimilar, Fusion Protein targeting CD40LG fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L
INN Name Dazodalibep
TargetCD40LG
FormatFusion Protein
Derivationsynthetic construct
Species Reactivityhuman
CH1 IsotypeFusion - Alternative to antigen receptors (domain scaffold: TNC-F3, tenascin domain F3) 2 TNC- F3 domains
VD LCFusion - Alternative to antigen receptors (domain scaffold: TNC-F3, tenascin domain F3) 2 TNC- F3 domains
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesViela Bio, Inc. (Gaithersburg MD USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development TechAlternative to antigen receptors, domain scaffold TNC F3, tenascin domain F3